Fungal Isolates of the Respiratory Tract in Symptomatic Patients Hospitalized in Pulmonary Units: A Mycological and Molecular Epidemiologic Study
Received 4 March 2020
Accepted for publication 10 July 2020
Published 22 July 2020 Volume 2020:13 Pages 661—669
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Zahra Rafat,1 Seyed Jamal Hashemi,1,2 Keyhan Ashrafi,3 Iraj Nikokar,4 Alireza Jafari,5 Abbas Rahimi Foroushani,6 Behrad Roohi,7 Zeinab Borjian Boroujeini,1 Niloofar Rashidi,1 Niki Najar-Shahri4
1Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; 2Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran; 3Department of Medical Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 4Laboratory of Microbiology and Immunology of Infectious Diseases, Paramedicine Faculty, Guilan University of Medical Sciences, Langeroud, Iran; 5Urology Research Center, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran; 6Department of Statistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; 7Department of Medical Mycology, Mazandaran University of Medical Sciences, Sari, Iran
Correspondence: Seyed Jamal Hashemi Tel +98 21 4293 3150
Fax +98 21 88951392
Introduction: Fungal respiratory infections are being recognized with increasing frequency in parallel with an expanding population of immunocompromised patients. In most cases, colonization is the first step in the progression to pulmonary fungal infection. This study was designed to evaluate the distribution of fungal elements in the respiratory tract of symptomatic patients hospitalized in pulmonary units.
Methods: This descriptive cross-sectional study was carried out over a period of two years, from October 2017 to October 2019 in Guilan province, located in Iran’s northern region. In the current study, bronchoalveolar lavage or sputum specimens were collected. All samples were analyzed by direct microscopy using KOH 10% and culture. Fungal identification was accomplished by internal transcribed spacer (ITS) and beta-tubulin sequencing. Also, in patients suspected of invasive pulmonary aspergillosis, BAL specimens were tested for galactomannan (GM) antigen.
Results: A total of 384 lung specimens (192 bronchoalveolar lavage (BAL) and 192 sputum samples) were obtained from symptomatic patients hospitalized in pulmonary units. Of these, 137 (35.67%) were positive in direct examination and culture. Among the 137 positive cases, most isolates were from male patients 86 (62.77%) and most of them were between 46 and 72 years. Candida albicans (37.22%) and Candida tropicalis (21.89%) represent the two most commonly isolated species in the current study. Cough (94.16%), dyspnea (81.02%), purulent sputum (62.04%) and weight loss (56.2%) were the predominant symptoms and tuberculosis (24.81%), chemotherapy (21.89%) and diabetes mellitus (19.70%) were the predominant underlying conditions. Also, 5 cases of invasive pulmonary aspergillosis and 1 case of mucormycosis were diagnosed.
Conclusion: Candida albicans was the most common fungal species isolated from symptomatic patients hospitalized in pulmonary units. Tuberculosis, chemotherapy and diabetes mellitus were important underlying conditions for pulmonary fungal colonization and/or infection.
Keywords: pulmonary fungal infection, bronchoalveolar lavage, sputum, respiratory tract, Iran
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]